Asked by: Liz Jarvis (Liberal Democrat - Eastleigh)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of expanding genetic for (a) the APOE4 gene and (b) other dementia-related risk factors in the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Pharmacogenomics and Medicine Optimisation NHS Genomic Network of Excellence convened a multidisciplinary meeting in November 2023 to support an impact assessment of potential testing for APOE-4 for prediction of risk of adverse events for lecanemab and donanemab. This group considered the evidence for expanding genomic testing for the APOE gene variants, including to inform other dementia related risk factors and concluded that there was insufficient evidence to offer genomic testing for the APOE gene variants as part of routine dementia care, risk assessment, or to first degree relatives of those with an already identified APOE variant to inform risk estimates of developing future Alzheimer's disease.
Asked by: Cat Smith (Labour - Lancaster and Wyre)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, on what dates his Department has met with patient groups representing families affected by sodium valproate since January 2024.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The current Parliamentary Under-Secretary of State for Women's Health and Mental Health, Baroness Merron, the previous minister with responsibility for sodium valproate and pelvic mesh redress policy, held a roundtable with representatives of the sodium valproate patient groups in December 2024.
Since then, I met with relevant stakeholders at various parliamentary events. I also met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.
Asked by: Damian Hinds (Conservative - East Hampshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential implications for her policies on community pharmacies of (a) business rates revaluation from April 2026 and (b) their exclusion from RHL reliefs.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government recognises that pharmacies are an integral ‘front door’ to the National Health Service, staffed by highly trained and skilled healthcare professionals.
In 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. Additional funding is also available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.
The Department will shortly consult with Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27. As part of this we will consider financial pressures on the sector.
Asked by: Scott Arthur (Labour - Edinburgh South West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of introducing the 2018 Nutrient Profiling Model on business investment in the food and drink sector.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. As part of this, the Government committed to updating the standards behind the restrictions on advertising ‘less healthy’ food or drink products on television before 9:00pm and online at any time, as well as the restrictions on the promotion of ‘less healthy’ food and drink products by location and volume price by applying the new Nutrient Profiling Model (NPM).
The advertising and promotions restrictions currently rely on the outdated NPM 2004/05. The new NPM has been updated in line with the latest dietary advice from the United Kingdom’s Scientific Advisory Committee on Nutrition, particularly in relation to free sugar and fibre. Applying it to the restrictions will strengthen these policies by bringing more products of concern for children’s health into scope.
The Government published the new NPM on 27 January. Application of the new NPM to the advertising and promotions restrictions would be subject to a full public consultation and an impact assessment of the costs to businesses and intended health outcomes.
Asked by: David Baines (Labour - St Helens North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability of diagnostic and treatment pathways for Tourette syndrome across Integrated Care Boards; and for what reason Tourette syndrome has not been included in the scope of the Independent Review into mental health conditions
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Integrated care boards (ICBs) are responsible for assessing local population need and commissioning appropriate diagnostic and treatment pathways for neurological conditions, including Tourette syndrome. While the Department has not undertaken a national assessment of provision across ICBs, we recognise the concerns raised about variation in diagnosis and support. To help address this, NHS England’s Getting It Right First Time (GIRFT) programme is working with ICBs to develop clear, consistent diagnostic and treatment pathways. The programme has appointed a clinical lead for children and young people's neurodevelopmental services, focusing on improving the assessment and management of Tourette syndrome.
The Independent Review into mental health conditions focuses on mental health conditions, ADHD and autism. Tourette’s is a neurological disorder and, therefore, it will be at the chair's discretion as to how far the review considers Tourette syndrome.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.
We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.
As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government plans to reinstate the Life Sciences Council.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.
The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.
Asked by: Kate Osamor (Labour (Co-op) - Edmonton and Winchmore Hill)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding provisions his Department has made in relation to the forthcoming National Tuberculosis Action Plan 2026–2031.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is currently developing the Tuberculosis National Action Plan for 2026 to 2031. The content of the plan, including any associated funding requirements, has not yet been finalised. Any proposals with financial implications will be subject to the usual cross‑Government processes, including agreement with HM Treasury. Details, with funding commitments, will be included when the plan is published.
Asked by: Baroness Ritchie of Downpatrick (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 January (HL13801), whether they plan to collect data on respiratory syncytial virus related hospital admissions of infants under one year old in weekly surveillance reports; if not, for what reason this data is being omitted.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Numbers of respiratory syncytial virus (RSV) admissions in infants are reported by a sentinel network of approximately 15 to 20 National Health Service trusts in England to the Severe Acute Respiratory Infections-Watch Surveillance at the UK Health Security Agency. Participation in this surveillance is completely voluntary for NHS trusts. Therefore, the number of participating trusts can vary from week to week, and comparisons based on simple counts may be misleading.
To provide appropriate context for reported weekly data, weekly admission rates are calculated to monitor trends over time. This uses trust catchment populations published by the Office for Health Improvement and Disparities, which are estimated for under five-year-olds, but which have not been estimated specifically for the under one year old age group, or infants.
Therefore, published rates are based on the available denominator data for the under five-year-olds, and these are publicly available in the national surveillance weekly reports and corresponding datafile at the GOV.UK website.
Further surveillance data and a programme impact assessment will be included in the annual surveillance report on RSV, due to be published in summer 2026. Please refer to the 2024/25 annual surveillance report for a summary of the previous winter season, which is available at the GOV.UK website.
Surveillance reports use hospital admission data and the Office for National Statistics’ mid-year estimates to model catchment populations for hospital trusts. Modelled catchment populations use hospital data, aggregated over three years and resident populations in five-year age bands.
Asked by: Baroness Redfern (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to work with Young Lives vs Cancer to deliver the travel fund for young cancer patients.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department knows that the cost of travel is an important issue for many young cancer patients and their families across the United Kingdom.
Through the National Cancer Plan, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from treatment. This commitment sits alongside wider action to transform cancer care for children and young people.
The Department has worked closely with the Children and Young People (CYP) Cancer Taskforce, to develop ambitious commitments on CYP cancer in the National Cancer Plan. The taskforce brought together experts across a range of fields to identify ways to improve outcomes and patient experience for young cancer patients and has been committed to ensuring the voices of key charity stakeholders and patients are included.
That’s why the Government assembled a Charity Sub-Group and Patient Experience Panel to ensure this expertise fed directly into the work of the taskforce.
The Government is committed to continuing its work with key cancer partners, including Young Lives vs Cancer, to deliver the commitments outlined in the National Cancer Plan.